How Well Does Switching to Oral Semaglutide Work Compared to Starting Fresh?
Oral semaglutide reduced blood sugar and weight when added to or switched from other incretin drugs, but was most effective in treatment-naive patients.
Quick Facts
What This Study Found
Oral semaglutide reduced HbA1c by 0.85% in naive patients, 0.67% in DPP-4i switchers, and 0.13% in GLP-1 RA switchers.
Key Numbers
- 368 participants with type 2 diabetes
- HbA1c change: naive group -0.85%, DPP-4 switch -0.67%, GLP-1 switch -0.13%
- DPP-4 and GLP-1 switch groups had significantly smaller HbA1c reductions vs naive (p significant)
- GLP-1 switch group lost less weight than naive group
- Dulaglutide-to-oral-semaglutide switch produced more weight loss than injectable-semaglutide-to-oral switch
How They Did This
Retrospective real-world analysis of 368 Japanese patients divided by prior incretin medication use.
Why This Research Matters
Many patients switch between diabetes medications. Understanding how prior therapy affects oral semaglutide's effectiveness helps guide treatment decisions.
The Bigger Picture
As oral GLP-1 options expand, understanding the diminished returns when switching between similar drug classes will be important for sequencing therapy.
What This Study Doesn't Tell Us
Retrospective study in Japanese patients; may not generalize. Relatively short 6-month follow-up. No randomization.
Questions This Raises
- ?Is switching from injectable to oral semaglutide justified for convenience despite reduced efficacy?
- ?Do longer follow-up periods show convergence of outcomes?
Trust & Context
- Key Stat:
- -0.85% HbA1c reduction in incretin-naive patients starting oral semaglutide
- Evidence Grade:
- Retrospective real-world study. Moderate quality for effectiveness comparison but lacks randomization.
- Study Age:
- Published in 2025.
- Original Title:
- Effectiveness for adding or switching from other incretin-related drugs to oral semaglutide in type 2 diabetes.
- Published In:
- Journal of diabetes investigation, 16(4), 608-614 (2025)
- Authors:
- Oya, Junko, Shimizu, Mika, Kubota, Ryo, Suda, Rika, Nagkagami, Tomoko
- Database ID:
- RPEP-12900
Evidence Hierarchy
Looks back at existing records to find patterns.
What do these levels mean? →Frequently Asked Questions
Is oral semaglutide as effective as injectable semaglutide?
Patients switching from injectable GLP-1 drugs to oral semaglutide saw smaller improvements than those starting fresh, suggesting injectable forms may be more potent.
Should I switch from my current diabetes medication to oral semaglutide?
This depends on your current treatment. Naive patients benefit most. Discuss with your doctor whether the convenience of an oral form justifies any trade-off in efficacy.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12900APA
Oya, Junko; Shimizu, Mika; Kubota, Ryo; Suda, Rika; Nagkagami, Tomoko. (2025). Effectiveness for adding or switching from other incretin-related drugs to oral semaglutide in type 2 diabetes.. Journal of diabetes investigation, 16(4), 608-614. https://doi.org/10.1111/jdi.14391
MLA
Oya, Junko, et al. "Effectiveness for adding or switching from other incretin-related drugs to oral semaglutide in type 2 diabetes.." Journal of diabetes investigation, 2025. https://doi.org/10.1111/jdi.14391
RethinkPeptides
RethinkPeptides Research Database. "Effectiveness for adding or switching from other incretin-re..." RPEP-12900. Retrieved from https://rethinkpeptides.com/research/oya-2025-effectiveness-for-adding-or
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.